SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : IMMUNE NETWORK RESEARCH (VSE:IMM)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: burner who wrote (61)5/25/1998 10:37:00 PM
From: burner  Read Replies (1) of 134
 
Private placement; appointment

Immune Network Research Ltd IMM
Shares issued 19,970,452 May 25 close $0.22
Mon 25 May 98 News Release
Mr. Victor Jones reports
The company has arranged a private placement of 500,000 units at 20 cents
per unit for total proceeds of $100,000 with each unit consisting of one
share and a half warrant, each one warrant to entitle the holder to
purchase one share at 20 cents for one year. The board of directors has
appointed Alex Rainard as vice-president, corporate affairs. He will be
assisting in the expansion of the company's research and medical projects
and financing. The board of directors has granted Mr. Rainard an option on
500,000 shares at 15 cents for five years.
The company is now on day 48 of its second phase live animal study on its
proprietary monoclonal antibody 1F7 involving nine macaques, seven of which
are infected with SHIV 89.6P. The macaques have received a series of five
injections of mAb 1F7 and the study includes blood and tissue sampling for
analysis of immune system response and virus load. The study is evaluating
the effectiveness of mAb 1F7 as an adjuvant or therapeutic for human
infection related to the AIDS virus. This research is financed under a
strategic partnership between the company and Immpheron Inc of Lexington,
KY, to continue research and development following earlier promising
findings on the effectiveness of mAb 1F7 to increase the breadth and
potency of virus neutralizing antibodies.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News